Evoke Pharma Statistics
Total Valuation
Evoke Pharma has a market cap or net worth of $23.03 million. The enterprise value is $16.57 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, before market open.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evoke Pharma has 2.16 million shares outstanding. The number of shares has increased by 151.70% in one year.
| Current Share Class | 1.72M |
| Shares Outstanding | 2.16M |
| Shares Change (YoY) | +151.70% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 8.07% |
| Owned by Institutions (%) | 20.89% |
| Float | 1.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 267.00 |
| PS Ratio | 2.06 |
| Forward PS | 4.85 |
| PB Ratio | 6.85 |
| P/TBV Ratio | 6.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 1.52.
| Current Ratio | 1.27 |
| Quick Ratio | 1.21 |
| Debt / Equity | 1.52 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.38 |
Financial Efficiency
Return on equity (ROE) is -134.88% and return on invested capital (ROIC) is -36.33%.
| Return on Equity (ROE) | -134.88% |
| Return on Assets (ROA) | -21.78% |
| Return on Invested Capital (ROIC) | -36.33% |
| Return on Capital Employed (ROCE) | -152.32% |
| Revenue Per Employee | $4.81M |
| Profits Per Employee | -$1.74M |
| Employee Count | 3 |
| Asset Turnover | 0.97 |
| Inventory Turnover | 0.79 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +144.39% in the last 52 weeks. The beta is -0.03, so Evoke Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.03 |
| 52-Week Price Change | +144.39% |
| 50-Day Moving Average | 6.26 |
| 200-Day Moving Average | 4.47 |
| Relative Strength Index (RSI) | 83.94 |
| Average Volume (20 Days) | 244,738 |
Short Selling Information
The latest short interest is 8,458, so 0.39% of the outstanding shares have been sold short.
| Short Interest | 8,458 |
| Short Previous Month | 17,639 |
| Short % of Shares Out | 0.39% |
| Short % of Float | 0.60% |
| Short Ratio (days to cover) | 0.31 |
Income Statement
In the last 12 months, Evoke Pharma had revenue of $14.42 million and -$5.23 million in losses. Loss per share was -$1.88.
| Revenue | 14.42M |
| Gross Profit | 13.99M |
| Operating Income | -5.19M |
| Pretax Income | -5.23M |
| Net Income | -5.23M |
| EBITDA | n/a |
| EBIT | -5.19M |
| Loss Per Share | -$1.88 |
Full Income StatementBalance Sheet
The company has $11.58 million in cash and $5.11 million in debt, giving a net cash position of $6.46 million or $3.00 per share.
| Cash & Cash Equivalents | 11.58M |
| Total Debt | 5.11M |
| Net Cash | 6.46M |
| Net Cash Per Share | $3.00 |
| Equity (Book Value) | 3.36M |
| Book Value Per Share | 1.56 |
| Working Capital | 3.30M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.32M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 97.02%, with operating and profit margins of -35.99% and -36.23%.
| Gross Margin | 97.02% |
| Operating Margin | -35.99% |
| Pretax Margin | -36.23% |
| Profit Margin | -36.23% |
| EBITDA Margin | n/a |
| EBIT Margin | -35.99% |
| FCF Margin | n/a |
Dividends & Yields
Evoke Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -151.70% |
| Shareholder Yield | -151.70% |
| Earnings Yield | -22.69% |
| FCF Yield | n/a |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 1, 2024. It was a reverse split with a ratio of 1:12.
| Last Split Date | Aug 1, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
Evoke Pharma has an Altman Z-Score of -11.39 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.39 |
| Piotroski F-Score | 3 |
